The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With Cardiovascular Risk
Status:
Recruiting
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
Numerous studies, but not all, have suggested a positive effect of allopurinol on the
cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol
therapy for improving cardiovascular outcomes in patients at high and very high
cardiovascular risk, excluding ischemic heart disease. This is particularly important due to
the high cost of cardiovascular disease treatment and its status as one of the leading causes
of death.